Combo Provides ' Broad Benefit ' Across NHL Subtypes Combo Provides ' Broad Benefit ' Across NHL Subtypes
The combination of copanlisib + rituximab led to a reduction in the risk for disease progression/death when compared with rituximab + placebo in patients with relapsed, indolent non-Hodgkin lymphoma.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Health | Hematology | Hodgkin's Disease | Lymphoma | Non-Hodgkin's Lymphoma | Rituxan